Epoetin Alfa for the Treatment of Anemia Resulting From Chronic Lymphocytic Leukemia

NCT00270049 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

195

Enrollment

INDUSTRY

Sponsor class

Conditions

Anemia
Leukemia, Lymphocytic, Chronic
Leukemia, Lymphocytic
Cancer
Neoplasms
Quality of Life

Interventions

DRUG: epoetin alfa

Sponsor

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.